Contributions of sensorial feedback to gait in Parkinson’s disease
Objective: To evaluate the integration of optic flow and proprioception when people with Parkinson's disease (PD), under and without dopaminergic medication effects, and matched-control group…Implications of direct and indirect costs in health-related quality of life in Parkinson’s disease: A cross-sectional study in Mexico
Objective: To evaluate the association of direct and indirect costs of Parkinson's disease (PD) and health-related quality of life (HRQoL) in a Mexican population. Background:…Impulsive-compulsive behaviors in patients with Parkinson’s disease and demographically-comparable group of healthy controls
Objective: To assess patients with Parkinson's disease (PwPD) impulsive-compulsive behaviors (ICBs) prevalence compared to healthy controls (HCs) group, to analyze PD clinical features, ICBs risk…Dynamic prediction for multiple repeated measures and event time data: An application to Parkinson’s disease
Objective: To develop methods for model-based personalized dynamic prediction of future outcome measure trajectories and risks of target events for the Parkinson's disease patients. Background:…Hospitalisation following different initial therapies in early Parkinson’s disease: Analysis of hospital episodes statistics from the PD MED EARLY trial
Objective: To compare hospitalisation rates of Parkinson's disease (PD) patients randomised between three different classes of oral medications used for early PD treatment. Background: PD…Conversion of patients from immediate release carbidopa-levodopa (IR CD-LD) and sustained release carbidopa-levodopa (SR CD-LD) to extended-release carbidopa-levodopa (ER CD-LD) in clinical practice
Objective: To evaluate the real-world response of patients who are converted from IR CD-LD and SR CD-LD to ER CD-LD in an academic practice. Background:…Developing a new home monitoring device for dyskinesia in Parkinson’s disease
Objective: To evaluate how accurately a new device can discriminate different clinical severities of dyskinesia from non-dyskinetic movements in patients with Parkinson's disease (PD). Background:…Real world conversion of levodopa to a novel extended release levodopa preparation: Determining predictors and dose ratios
Objective: To determine predictors of response and conversion ratios for a novel extended release levodopa preparation. Background: A new extended release levodopa preparation, Rytary®, has…Levodopa-carbidopa intestinal gel via PEG-J for advanced Parkinson’s disease- A single centre experience
Objective: To investigate clinical outcome and possible complications of LCIG in patients with advanced PD in years 2006-2014 at Helsinki University Hospital. Background: Continuous levodopa-carbidopa…A randomized controlled clinical study to evaluate efficacy, safety and tolerability of SC L-dopa/carbidopa (ND0612H) infusion regimens in fluctuating PD patients
Objective: To evaluate the efficacy, safety & tolerability of continuous subcutaneous infusion regimens of ND0612H. Background: L-dopa remains the most effective PD medication, however oral…
Abstracts from the International Congress of Parkinson’s and Movement Disorders.